Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation
The SURPASS-CVOT trial is a phase 3, randomized, double-blind cardiovascular outcomes trial that will assess tirzepatide for both non-inferiority and superiority against dulaglutide. For dulaglutide, this effect is already proven: According to the Trulicity website, the drug may be used in adults with type 2 diabetes to reduce the risk of major cardiovascular events (problems having to do with the heart and blood vessels) such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors. How do I know which medication is right for me
GLP-1 drugs (Ozempic, Wegovy, and Zepbound) treat conditions like Type 2 diabetes, heart disease, and obesity
A body lotion for women that keeps your skin looking radiant and feeling pampered all day
[80], the normalization of HbA1c induced by oral semaglutide is directly associated with the reduction in cardiovascular risk, but it may not be related simply to improvement in glycaemic control
